VIP: The Body's Anti-Inflammatory Peptide

What is VIP?

Vasoactive intestinal peptide, usually shortened to VIP, is a small signaling peptide that the human body produces naturally. It was first identified for its effects on the gut and blood vessels, which is where its name comes from, but researchers have since learned that it acts throughout the body as a messenger between the nervous and immune systems.

Because the body already makes VIP, therapeutic interest centers on situations where its own signaling may fall short, or where adding more might help calm overactive inflammation. A synthetic form, aviptadil, has been used in clinical research and is the basis for the most rigorous human studies to date.

How it works

In immunology, VIP is described as an anti-inflammatory, immunoregulatory signal. It can shift immune activity away from a pro-inflammatory state and toward a more balanced one, influencing the behavior of immune cells and the chemical messengers they release. This understanding rests on a substantial body of research, including a key review of VIP's significance in immunomodulation.

VIP also relaxes smooth muscle and dilates blood vessels and airways, which helps explain why much of the clinical research has focused on the lungs. These are mechanisms observed in laboratory and preclinical settings as well as in early human work, and they describe how VIP may act rather than proving a specific clinical outcome in any given person.

What the research shows

The most controlled human evidence comes from a 2022 randomized controlled trial published in Critical Care Medicine, which tested intravenous VIP (aviptadil) in 196 patients with critical COVID-19 respiratory failure and followed outcomes over 60 days. The trial's primary endpoint, being alive and free of respiratory failure at day 60, did not reach statistical significance. The researchers did report a roughly two-fold improvement in the odds of survival at 60 days, along with reduced interleukin-6, an inflammatory marker, by day 3.

This is the largest controlled human dataset for VIP, and randomized controlled trials are the strongest form of clinical evidence, though this one tested a narrow, severe condition rather than general health. The underlying trial program is registered on ClinicalTrials.gov as NCT04311697.

A 2010 phase 2 clinical trial in the American Journal of Respiratory and Critical Care Medicine examined inhaled VIP in 20 patients with sarcoidosis, an inflammatory lung disease. The investigators reported that nebulized VIP was well tolerated, reduced production of the inflammatory cytokine TNF-alpha, and increased regulatory T cells, the first demonstration of an immunoregulatory effect of VIP in humans. The finding supports the mechanism described above. As a phase 2 study, it was sized to test signal and safety, not to prove benefit.

The research has also moved toward longer-acting forms of VIP. Pemziviptadil (PB1046), a sustained-release VIP analogue given as a once-weekly subcutaneous injection, was evaluated in a phase 2 trial in adults with pulmonary arterial hypertension (NCT03556020), measuring effects on pulmonary vascular resistance and exercise capacity. The study was terminated early, which is common in drug development, but it shows where VIP research is heading: toward longer-acting forms and chronic vascular conditions.

Taken together, the human research is real, specific, and clusters around inflammatory and respiratory conditions. Much of what is known about VIP beyond these trials sits at the mechanism level, and the clearest findings so far are condition-specific rather than broad claims about wellness, recovery, or longevity.

What it's being explored for

VIP is being explored mainly for inflammation and immune regulation, with the clearest human signals in lung conditions: COVID-19 respiratory failure, sarcoidosis, and pulmonary arterial hypertension. Its natural anti-inflammatory and smooth-muscle-relaxing roles are what draw scientific interest, and the next wave of work centers on longer-acting analogues that could extend those effects beyond acute settings.

Whether VIP is appropriate for any individual is a question for a qualified physician after a full assessment.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. VIP is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.